Targeting by PG545 enhances PARP inhibitor response in ovarian cancer

PG545 sensitizes ovarian cancer cells to PARP inhibitors through modulation of RAD51-DEK interaction

Full article: Veliparib (ABT-888), a PARP inhibitor potentiates the cytotoxic activity of 5-fluorouracil by inhibiting MMR pathway through deregulation of MSH6 in colorectal cancer stem cells

HMGB3 promotes PARP inhibitor resistance through interacting with PARP1 in ovarian cancer

Cancers, Free Full-Text

HMGB3 promotes PARP inhibitor resistance through interacting with PARP1 in ovarian cancer

HMGB3 promotes PARP inhibitor resistance through interacting with PARP1 in ovarian cancer

Biomolecules, Free Full-Text

One more step toward treatment of PARP inhibitor-resistant ovarian cancers

Cancers, Free Full-Text

PARP Inhibitors Synergize with b-Lap against Orthotopic MiaPaCa2 PDA

Synergistic effects of PG545 and gemcitabine co-treatment on pancreatic

Frontiers Immunotherapy in Ovarian Cancer: Thinking Beyond PD-1/PD-L1

Biomolecules, Free Full-Text

A) Co-treatment of QC and autophagy inhibitor Bafilomycin A in C13

Targeting by PG545 enhances PARP inhibitor response in ovarian cancer